News 10.09.2025 Switzerland, 10 September 2025 – CUTISS, a late-stage clinical TechBio at the forefront of tissue therapeutics and regenerative medicine, has announced the closing of its Series C round for a total of CHF 56M with existing and new investors, bringing total funds raised to more than CHF 125M. The proceeds will...
News 09.09.2025 Topadur Pharma AG today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational therapy TOP-N53 for the treatment of digital ulcersin patients with systemic sclerosis. Systemic sclerosis is a rare, life-threatening autoimmune disease characterized by fibrosis, vascular damage, and chronic digital ulcers that...
News 08.09.2025 InSphero AG, the pioneer in scalable 3D in vitro technologies for drug safety and efficacy testing, announced the appointment of Dr. Werner Lanthaler, Managing Director of Wlanholding GmbH, former Chief Executive Officer of Evotec SE, and former CFO of Intercell AG, to its Board of Directors. Dr. Lanthaler led Evotec for 16 years, during which he guided the...
News 05.09.2025 AL-S Pharma today announced positive topline results from the Phase 2 clinical study evaluating AP-101, a potential first-in-class, disease-modifying treatment for amyotrophic lateral sclerosis (ALS). AP-101 is a monoclonal antibody targeting misfolded SOD1, a key pathology in both sporadic ALS and mutant SOD1-ALS.1 AP-101, in addition to standard of care, met...
News 26.08.2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate...